Literature DB >> 12392349

Long-term treatment of bipolar disorder with lamotrigine.

Joseph R Calabrese1, Melvin D Shelton, Daniel J Rapport, Susan E Kimmel, Omar Elhaj.   

Abstract

Bipolar depression is as debilitating as mania in bipolar disorder, but the treatment of bipolar depression has historically received less attention. To date, there is no mood stabilizer (liberally defined as a medication that decreases episode severity, duration, or frequency in one phase of bipolar illness without producing a negative effect in other phases) that demonstrates similar efficacy in both the depressive and the manic phases of bipolar disorder. However, bipolar depression--which is prevalent, sometimes chronic, and associated with a low quality of life and a high risk of suicide--must be addressed as energetically as mania. Recent research into the long-term treatment of bipolar disorder has raised several questions about the generalizability of early lithium studies, as a result of these studies' designs. Researchers conducting more recent studies of mood stabilizers in the long-term treatment of bipolar disorder have attempted to clarify their results by, for example, performing survival analyses of the data. Until pharmacotherapy has been found that is equally efficacious in the treatment of both manic and depressive episodes in bipolar disorder, the use of combination therapy to manage bipolar disorder is advised. Lithium and divalproex sodium remain the first-line treatments for mania. Lamotrigine has been found to have acute efficacy in treating episodes of bipolar depression without increasing cycling or provoking a switch into mania, as well as a long-term role in delaying relapse and recurrence of depressive episodes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12392349

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

Review 1.  Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans.

Authors:  Mireille Basselin; Epolia Ramadan; Stanley I Rapoport
Journal:  Brain Res Bull       Date:  2011-12-09       Impact factor: 4.077

2.  Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy.

Authors:  Shuchi Desai; Sadia Khanani; Mujeeb U Shad; E Sherwood Brown
Journal:  J Clin Psychopharmacol       Date:  2009-06       Impact factor: 3.153

3.  Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat.

Authors:  Shagufta Ahmad; Leslie J Fowler; Peter S Whitton
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

4.  Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study.

Authors:  Willie R Earley; Maria V Burgess; Barbara Khan; Ludmyla Rekeda; Trisha Suppes; Mauricio Tohen; Joseph R Calabrese
Journal:  Bipolar Disord       Date:  2019-11-06       Impact factor: 6.744

5.  Antidepressant and pro-motivational effects of repeated lamotrigine treatment in a rat model of depressive symptoms.

Authors:  Simona Scheggi; Teresa Pelliccia; Alessandro Cuomo; Maria Graziella De Montis; Carla Gambarana
Journal:  Heliyon       Date:  2018-10-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.